UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021583
Receipt number R000024891
Scientific Title Evaluation of the effect of rosuvastatin on renoprotective effect
Date of disclosure of the study information 2016/03/25
Last modified on 2020/04/02 09:16:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the effect of rosuvastatin on renoprotective effect

Acronym

Rosuvastatin-kidney study

Scientific Title

Evaluation of the effect of rosuvastatin on renoprotective effect

Scientific Title:Acronym

Rosuvastatin-kidney study

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluaton of the protective effect of rosuvastatin on the diabetic podocyte injury

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of urinary nephrin excretion after 6 months

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Once daily 2.5 mg of Rosuvastatin is administerd during 6 months

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient with hyperchoresterolemia
Patients whose urinary albumin secretion is below 300 mg/gCr

Key exclusion criteria

Patient is started or changed renin angiotensin system inhibitor.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Makino
Middle name
Last name Hisashi

Organization

National Cerebral and Cardiovascular Center

Division name

Division of Atherosclerosis and Diabetes

Zip code

565-0873

Address

5-7-1 Fujishirodai, Suita, Osaka, Japan

TEL

06-6833-5012

Email

makinoh@hsp.ncvc.go.jp


Public contact

Name of contact person

1st name Makino
Middle name
Last name Hisashi

Organization

National Cerebral and Cardiovascular Center

Division name

Division of Atherosclerosis and Diabetes

Zip code

565-0873

Address

5-7-1 Fujishirodai, Suita, Osaka, Japan

TEL

06-6833-5012

Homepage URL


Email

makinoh@hsp.ncvc.go.jp


Sponsor or person

Institute

Rosuvastatin-kidney study group

Institute

Department

Personal name



Funding Source

Organization

AstraZeneca

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cerebral and Cardiovascular Center

Address

5-7-1 Fujishirodai, Suita, Osaka, Japan

Tel

06-6833-5012

Email

makinoh@ncvc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 03 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 11 Month 26 Day

Date of IRB


Anticipated trial start date

2015 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 03 Month 23 Day

Last modified on

2020 Year 04 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024891


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name